Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality

Myelodysplastic syndrome (deletion 5q) - lenalidomide: equality impact assessment - guidance development (PDF 269 KB)

Myelodysplastic syndrome (deletion 5q) - lenalidomide [ID480]: final appraisal determination 2 information

Myelodysplastic syndrome (deletion 5q) - lenalidomide [ID480]: final appraisal determination document (PDF 446 KB)

Myelodysplastic syndrome (deletion 5q) - lenalidomide [ID480]: evaluation report information

Myelodysplastic syndrome (deletion 5q) - lenalidomide [ID480]: evaluation report (PDF 2.3 MB)

Myelodysplastic syndrome (deletion 5q) - lenalidomide: appraisal consulation 2

Myelodysplastic syndrome (deletion 5q) - lenalidomide: appraisal consultation document 2 information

Myelodysplastic syndrome (deletion 5q) - lenalidomide: evaluation report information

Myelodysplastic syndrome (deletion 5q) - lenalidomide: evaluation report (PDF 2.53 MB)

Myelodysplastic syndrome (deletion 5q) - lenalidomide: final appraisal determination information

Myelodysplastic syndrome (deletion 5q) - lenalidomide: final appraisal determination document (PDF 392 KB)

Myelodysplastic syndrome (deletion 5q) - lenalidomide: evaluation report information

Myelodysplastic syndrome (deletion 5q) - lenalidomide: evaluation report (PDF 2.62 MB)

Myelodysplastic syndrome (deletion 5q) - lenalidomide: appraisal consultation

Myelodysplastic syndrome (deletion 5q) - lenalidomide: appraisal consultation document information

Myelodysplastic syndrome (deletion 5q) - lenalidomide: evaluation report information

Myelodysplastic syndrome (deletion 5q) - lenalidomide: evaluation report (PDF 8.67 MB)

Myelodysplastic syndrome (deletion 5q) - lenalidomide: response to comments on the draft scope and provisional matrix (PDF 129 KB)

Myelodysplastic syndrome (deletion 5q) - lenalidomide [ID480]: equality impact assessment - scoping (PDF 51 KB)

Myelodysplastic syndrome (deletion 5q) - lenalidomide: final scope (PDF 50 KB)

Myelodysplastic syndrome (deletion 5q) - lenalidomide: final matrix (PDF 56 KB)

Appendix B - draft scope for consultation (pre-referral) - March 2011 (PDF 58 KB)

Appendix C - provisional matrix (pre-referral) - March 2011 (PDF 60 KB)